Category: breast cancer

  • Syapse, Pfizer Extends Collaboration to Generate Real-World Evidence in Breast Cancer

    What You Should Know: – Syapse, a real-world evidence company that informs cancer care, announced that it will extend its collaboration with Pfizer to generate real-world evidence in breast cancer. – This is the third phase of the collaboration, which was first announced in 2019 and renewed in 2021. Generate Real-World Evidence in Breast Cancer […]

  • Can Alcohol Cause Cancer?

    If even light drinking can cause cancer, why don’t doctors warn their patients about it? As I discuss in my video Can Alcohol Cause Cancer?, we’ve known about “the possible association of the consumption of alcohol with excessive mortality from cancer” for more than a hundred years. Though there is “accumulating evidence that alcohol drinking […]

  • How to Balance the Risks and Benefits of Mammograms

    Fact boxes can quantify benefits and harms in a clear and accessible format.  When it comes to cancer screening, doctors “have too often ignored” the fact that women may place different weights on various pros and cons, so they have just “focused on persuading rather than educating” and letting people make up their own mind. […]

  • Doctors Tested for Basic Understanding of Mammogram Math

    If doctors don’t understand health statistics, how can they possibly properly counsel patients?  “In these mammography wars, rational thinking can be easily lost.” Mammograms are big business, bringing in about seven billion dollars a year, but it would be a bit too “cynical to believe” that the pushback from mammogram critics “stems only from self-interest […]

  • Breast Cancer Can Grow and Spread for Decades Before “Early” Detection

    “Early” detection is actually really late. Without mammograms, breast cancer may not be caught for an average of 22.8 years. With mammograms, though, breast cancer may only grow and spread for…21.4 years. Critics of breast cancer screening claim that, on a population scale, mammograms have never been shown to actually prolong women’s lives on average. […]

  • Learn More Than 97% of Doctors About Lead-Time Bias

    After reading this, you’ll know more than an estimated 97 percent of doctors about a critical concept called lead-time bias.  While running for president of the United States, former New York mayor Rudy Giuliani ran a campaign ad contrasting his 82 percent chance of surviving prostate cancer in the United States with the 44 percent […]

  • AZ eyes FDA verdict on Lynparza in adjuvant breast cancer in Q1

    The FDA will deliver a verdict on AstraZeneca’s PARP inhibitor Lynparza as an adjuvant treatment for breast cancer in the first quarter of next year, after granting the application a priority review. AZ and partner Merck & Co have filed Lynparza (olaparib) for use in BRCA-mutated, HER2-negative early breast cancer in patients who have already […]

  • Second FDA okay for Therapixel’s AI-based mammography tool

    France’s Therapixel has secured a second FDA approval for MammoScreen, its artificial intelligence-powered software for detecting cancerous lesions in mammogram images. MammoScreen was approved last year for use alongside conventional digital 2D mammography, and has now been given a green light by the FDA for use with 3D mammograms, also known as digital breast tomosynthesis. […]

  • THCB Spotlights: Maya Said, CEO, Outcomes4Me

    Today on THCB Spotlights, Matthew Holt talks with Maya Said, the CEO of Outcomes4Me, which works in the cancer patient empowerment space. Outcomes4Me is a patient empowerment platform that helps patients diagnosed or in active treatment for breast cancer understand their situation and treatment options, as well as connect better with providers to enable meaningful […]

  • Fewer Than One in Ten Informed About Most Serious Downside of Mammograms

    What do nine in ten women say they were never told about mammograms, even though they thought they had the right to know? “Fueled by economic conflicts of interest”—with the multibillion-dollar mammogram industry—“and good intentions…many women [are] being given diagnoses of breast cancer that they did not need, producing unwarranted fear and psychological stress and […]

  • Overtreatment of Ductal Carcinoma In Situ

    Nine out of ten women don’t realize that some breast cancers would never have caused any problems or even become known in one’s lifetime. This is an issue ductal carcinoma in situ has brought to the forefront. The whole point of cancer screening is to “detect life-threatening disease at an earlier, more curable stage. Effective […]

  • Those Who Claim the Greatest Benefit From Mammograms May Ironically Suffer the Most Harm

    The mammogram paradox is that women who are harmed the most, are the ones who claim the greatest benefit. While false-positive results, pain during the procedure, and radiation exposure may be among the most frequent harms associated with mammogram screening, overdiagnosis “is now recognized as the most serious downside of population breast screening.” Overdiagnosis is […]

  • Personalized Screening is Key to Breast Imaging AI Market Reaching $205M by 2025

    Dr. Sanjay M. Parekh Ph.D. , Sr Market Analyst at Signify Research Ltd. As October draws to a close, so does Breast Cancer Awareness Month (BCAM), or National Breast Cancer Awareness Month (NBCAM) as it is known in the US. Breast imaging AI vendors are heavily promoting this initiative to raise awareness of the disease […]

  • How Much Cancer Do Mammograms Cause?

    What is the risk-benefit ratio of the cancers picked up by mammograms and the cancers caused by mammograms? Over the last few decades, our radiation exposure has nearly doubled, due almost exclusively to medical sources, such as CT scans. While we’ve known that higher dose radiation from CT scans and angiograms, for example, can cause […]

  • Seagen’s breast cancer drug Tukysa turned down by NICE

    NICE has decided not to recommend Seagen’s orally-active HER2 inhibitor Tukysa for advanced breast cancer in draft guidance, saying it isn’t a cost-effective use of NHS resources. Tukysa (tucatinib) was approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) in February as a third-line treatment for HER2-positive breast cancer, shortly after it was […]

  • Do Mammograms Have to Be Painful?

    Excessive breast compression during mammography may not improve image quality and can cause unnecessary pain.  False-positive results have been described as “the most frequent harm” associated with mammogram screening, but it actually may be the pain. “There is a wide variation both in the reported frequency of pain and in degree of pain felt by […]

  • Most Women May Experience at Least One False-Positive Mammogram

    Odds are most women will get at least one false-positive mammogram, but, thankfully, most women who are called back for further testing of a suspicious mammogram finding do not end up having cancer after all.  In response to the Swiss Medical Board’s recommendation against women of any age getting routine mammograms, critics suggested that instead […]

  • How Is It Possible That Mammograms Don’t Actually Save Lives?

    For every life saved by mammography, as many as two to ten women are overdiagnosed and unnecessarily turned into breast cancer patients with all of the attendant harms of chemo, radiation, or surgery, without the benefits. What was the impact of the 2009 shift in recommendations by the U.S. Preventive Services Task Force (USPSTF) to […]

  • Why Doctors Should Not Encourage Breast Self-Exams

    Various health organizations offer clashing mammogram recommendations that range from annual mammograms starting at age 40 to eliminating routine mammograms altogether. Who can you trust? Clashing mammogram recommendations ranging from annual mammograms starting at age 40 to eliminating routine mammograms altogether are offered by various health organizations. It’s hard to know who to trust given […]

  • Enhertu nabs speedy FDA review for earlier use in breast cancer

    Hard on the heels of impressive new data for Enhertu as a second-line therapy for breast cancer, AstraZeneca and Daichi Sankyo have claimed FDA breakthrough status for the drug that should shorten its review time. The new designation for Enhertu (trastuzumab deruxtecan) is based on the results of the DESTINY-Breast03 trial, which showed that the […]

  • Why Are Mammogram Guidelines Conflicting? 

    When women are fully informed about the risks and benefits of mammograms, 70 percent may choose not to get screened. You may be in that 30 percent who opts to get a mammogram and absolutely have the right to decide for yourself.  “For nearly a century, public health organizations, professional associations, patient advocacy groups, academics, and clinicians largely viewed cancer screening as a simple, […]

  • 90% of Women Appear Misinformed About Mammograms 

    Most women are just being told what to do, rather than being given the facts needed to make a fully informed decision.   “Selling cancer screening can be easy,” begins an editorial in the Journal of the National Cancer Institute. “Induce fear by exaggerating risk. Offer hope by exaggerating the benefit of screening. And don’t mention harms [caused by the screening]. It is especially easy […]

  • ESMO21: Roche’s giredestrant takes stage in battle of the oral SERDs

    Roche has revealed the first phase 2 clinical data with giredestrant, one of a clutch of new selective oestrogen receptor degraders (SERDs) hoping to provide an oral alternative to AstraZeneca’s injectable Faslodex for breast cancer. The Swiss drugmaker presented results from its coopERA trial of giredestrant in post-menopausal women with hormone receptor (HR)-positive, HER2-negative early […]

  • The Effects of Nutritional Yeast for Cancer 

    How can the beta glucan fiber in brewer’s, baker’s, and nutritional yeast improve wound healing and, potentially, anti-cancer immunity?  My video Benefits of Nutritional Yeast for Cancer opens with an image of an article titled “The Treatment of Inoperable Cancer.” It noted that “200 years ago it was observed that a certain number of malignant growths disappeared after an attack of erysipelas [a type of […]

  • Evidence lacking for AI-based breast cancer screening  

    A review of 12 studies about AI systems used to screen patients for breast cancer found that they lacked evidence to prove that they would work well in a clinical setting. Researchers highlighted concerns about study quality, including the fact that all of the studies were retrospective and many of them had a high risk […]

  • Soy Phytoestrogens for Menopausal Symptoms

    Does soy food consumption explain why Japanese women appear to be so protected from hot flash symptoms? When women hit menopause and their ovaries shut down, the estrogen level in their body drops 95 percent. This is good news for the endometrium, the lining of the uterus. Otherwise, the constant estrogen signaling could eventually result in endometrial cancer. In fact, […]

  • NICE changes stance on Lilly’s breast cancer dug Verzenio

    After rejecting Eli Lilly’s Verzenio for breast cancer therapy earlier this year, NICE has relented, recommending the drug for routine NHS use alongside hormonal therapy fulvestrant. A final appraisal document from the health technology assessment (HTA) agency backs the use of Verzenio (abemaciclib) alongside fulvestrant for the treatment of women with hormone receptor-positive, HER2-negative breast […]

  • Breast cancer drug approved for NHS after maker agrees discount

    Reversal of earlier rejection by Nice of abemaciclib – known as Verzenios – is welcomed by campaigners A breast cancer drug that was rejected for routine NHS use in England earlier this year has now been recommended by health officials after a discount was agreed with the manufacturer. The decision has been described as “fantastic […]

  • HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn

    Seagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate that could challenge rival drugs from AstraZeneca/Daiichi Sankyo and Roche. The US company is paying $200 million upfront for rex-Asian rights to RemeGen’s disitamab vedotin, with another $2.4 billion in possible future payments tied to future successes […]

  • Pfizer puts up $1bn to buy into Arvinas breast cancer programme

    Pfizer has pledged a whopping $11 billion upfront for rights to an Arvinas drug for breast cancer from its protein degrader platform, which harnesses cells’ natural protein-denaturing machinery to remove rogue proteins associated with disease. The deal focuses on ARV-471, currently in phase 2 testing for advanced breast cancer patients whose tumours expresses oestrogen receptors […]

  • Dr. Amit Agarwal Interview

    Sonam: Hello everyone, today we have on our panel discussion round doctor Amit Agarwal with us who is Director Medical Oncology from Fortis Hospital Shalimar Bagh. We welcome your doctor on board. Dr. Amit: Thank you Sonam: So to let you know about Doctor Amit. Doctor Amit brings with him an experience of more than […]

  • ASCO 2021 recap: Lynparza’s lift, Grail goes on, LAG validation & more

    The American Society of Clinical Oncology’ annual meeting featured news highlights from the Merck, Novartis, and other drug giants. Meanwhile, some small biotechs rode the coattails of their larger counterparts and others forged their own paths with promising early results for new cancer drug targets.

  • ASCO21: Lynparza aces adjuvant breast cancer therapy trial

    AstraZeneca and Merck & Co’s Lynparza is primed for even wider use in the treatment of breast cancer after a phase 3 trial showed it could extend the time for the cancer to return when used as adjuvant therapy. Giving Lynparza (olaparib) to women with BRCA-positive, HER2-negative breast cancer straight after chemotherapy and surgery to […]

  • ViewPoints Interview: Daiichi Sankyo’s Ken Keller Shares Insights on NICE Recommendation for Enhertu in HER2 Positive Breast Cancer

    In an interview with PharmaShots, Ken Keller, President and Chief Executive Officer at Daiichi Sankyo and Global Head of the Daiichi Sankyo Oncology Business shared his views on the NICE CDF recommendation for Enhertu in unresectable or metastatic HER2 positive breast cancer and the company’s growth and pipeline. Shots: The recommendation from NICE is based on […]

  • Off Our Chests: No Secrets Left Behind

    By CHADI NABHAN She was a successful corporate lawyer turned professional volunteer and a housewife. He was a charismatic, successful, and world-renowned researcher in gastrointestinal oncology. He was jealous of all breast cancer research funding and had declared that disease his nemesis. They were married; life was becoming a routine, and borderline predictable. Both appeared […]

  • AZ/Daiichi unveil data from TNBC hopeful datopotamab deruxtecan

    AstraZeneca and Daiichi Sankyo have revealed new data from datopotamab deruxtecan in triple negative breast cancer (TNBC) – and although it’s from a small patient group results look impressive. To recap, AZ shelled out $1bn for rights to datopotamab last year, an antibody-drug conjugate (ADC) consisting of an antibody that targets tumours and a lethal […]

  • Are Avocados Associated with Greater Risk or Reduced Risk of Cancer?

    Avocado consumption can improve artery function, but what effect might guacamole have on cancer risk? In my last video about avocados, The Effects of Avocados and Red Wine on Meal-Induced Inflammation, I described their anti-inflammatory effects and cholesterol- and triglyceride-lowering effects, but what about the Are Avocados Good for You? video I did years ago […]

  • Natural Dietary Treatments for Fibroids

    The same diet that helps regulate hormones in women may also reduce exposure to endocrine-disrupting pollutants. Fibroids are the most common benign tumors in women. They can grow to a foot in diameter and affect the majority of women before they hit menopause. Although fibroids tend to be asymptomatic, when symptoms do occur, they tend […]

  • Tecentriq can stay as therapy for triple-negative breast cancer, FDA experts say

    Roche’s Tecentriq can stay on the US market as a therapy for triple negative breast cancer, advisers to the FDA have said as part of a review of several quickly-approved cancer drugs. Tecentriq was the first drug to be discussed in the review by the FDA’s Oncologic Drugs Advisory Committee (ODAC) of cancer drugs that […]

  • Enhertu cleared for NHS use via Cancer Drugs Fund

    NICE has recommended the use of AstraZeneca and Daiichi Sankyo’s Enhertu in draft guidance, the first time the drug has been commissioned in any European country.  The UK health technology assessment (HTA) agency has backed Enhertu (trastuzumab deruxtecan) as a therapy for HER2 positive breast cancer which can’t be surgically removed or which has spread […]

  • Should You Get an Annual Health Check-Up?

    What are the risks and benefits of getting an annual check-up from your doctor? Physicians and patients have come to expect the annual check-up as a routine part of care. “However, considerable research has not demonstrated a substantial benefit,” so a “revolt is brewing against the tradition of periodic” check-ups. “Even the Society for General […]

  • Gilead scores US approval for breast cancer drug that wowed ESMO

    Gilead’s $21 billion purchase of Immunomedics and its potential blockbuster Trodelvy continues to pay off, as the drug has now been approved by the FDA for triple-negative breast cancer.  Trodelvy (sacituzumab govitecan) was granted accelerated approval by the FDA in April last year, and is now indicated for adults with triple-negative breast cancer who have […]

  • Helpful Foods to Support People with Autism

    The sulforaphane found in five cents’ worth of broccoli sprouts has been shown to benefit autism in a way no drug ever has in a randomized, double-blind, placebo-controlled study. You may remember my series of videos, which includes Prevent Cancer from Going on TOR, about target of rapamycin (TOR), the engine-of-aging enzyme. Kids with autism […]

  • Are Lectins in Food Good or Bad for You?

    Might lectins help explain why those who eat more beans and whole grains have less cancer? Lectins are to blame for the great “white kidney bean incident” of 2006 in Japan. One Saturday evening, a TV program introduced a new method to lose weight. The method was simple: toast some dry, raw, white kidney beans […]

  • Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval

     Novartis announced the Health Sciences Authority (HSA) has approved* Piqray®, an α-specific class I phosphatidylinositol-3-kinase (PIK3CA) inhibitor, for the treatment of postmenopausal women, and men, with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2-) negative, advanced breast cancer with a PIK3CA mutation in combination with fulvestrant after disease progression following an endocrine-based regimen. […]

  • Life-extending drug for incurable breast cancer approved for NHS use

    About 3,300 women a year may benefit from decision to approve ribociclib Women with incurable advanced breast cancer will be able to get a drug from the NHS that can potentially extend their life by almost eight months, under new guidance. The National Institute for Health and Care Excellence (Nice) has approved the drug – […]

  • NICE okays regular NHS funding for Novartis’ breast cancer drug Kisqali

    NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients. In the final draft guidance, NICE recommended Kiskali be taken out of the Cancer Drugs Fund, which has been providing interim reimbursement since 2019 until further trial data emerged addressing uncertainties about overall […]

  • Filing beckons as Lynparza hits the mark in adjuvant breast cancer

    AstraZeneca’s PARP inhibitor Lynparza has shown a clinical benefit when given as an adjuvant for early breast cancer, according to the data monitoring body for the phase 3 OlympiA trial.  At an interim analysis, Lynparza (olaparib) reduced recurrence of disease compared to placebo in women with BRCA-mutated, HER2-negative breast cancer after surgery and chemotherapy to […]

  • A Patient Engagement Strategy Needs to Deliver a Holistic Experience

    Chris Evanguelidi, Director, Enterprise Healthcare Market for Redpoint Global Inc. Researchers from Johns Hopkins published a study in October on the impact of the pandemic on health care delivery. Among its findings, the data show a 21.4% decrease in primary care visits in Q2 of 2020, compared against the average volume of Q2 visits for […]

  • Volpara Acquires Breast Cancer Risk Assessment Platform CRA Health for $18M

    What You Should Know: –  Volpara Health, an integrated breast care platform assisting in the delivery of personalized patient care has acquired breast cancer risk assessment platform CRA Health. – CRA Health, LLC, is a breast cancer risk assessment company spinoff from Massachusetts General Hospital — a Harvard Medical School teaching hospital. Today the company delivers more […]

  • Arsenic in Rice Milk, Rice Krispies, and Brown Rice Syrup

    I recommend people switch away from using rice milk For kids and teens, the amount of arsenic flowing through their bodies was found to be about 15 percent higher for each quarter cup of rice consumed per day, and a similar link was found in adults. A study of pregnant women found that consuming about […]

  • MacroGenics’ HER2 breast cancer drug Margenza approved in US

    MacroGenics’ HER2-targeted breast cancer drug Margenza has been approved by the FDA, challenging several recently approved drugs with a narrow efficacy edge over Roche’s Herceptin in data gathered so far in advanced disease. Margenza (margetuximab) won FDA approval in combination with chemotherapy to treat metastatic HER2-positive breast cancer after at least two previous rounds of […]

  • Daiichi Sankyo, AZ close on EU approval of Enhertu for breast cancer

    Daiichi Sankyo and AstraZeneca could be just weeks away from an EU approval for their antibody-drug conjugate (ADC) for breast cancer – Enhertu – which is tipped to become a multibillion-dollar blockbuster. At its meeting last week, the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of Enhertu (trastuzumab deruxtecan) for patients […]

  • The Antioxidant Power of Açaí vs. Apples

    There are so many açaí products on the market now, from frozen pulp in smoothie packs to freeze-dried powder and supplements. How is it eaten traditionally? “In the Brazilian Amazon, the Indian tribes of the forest cut down the tree and eat the palm heart…then urinate on the rest of the tree to attract a […]

  • Merck & Co buys cancer biotech VelosBio for $2.75bn

    Merck & Co has agreed to buy California biotech VelosBio and its experimental cancer drug for $2.75 billion in cash. Known as MSD outside North America, the big pharma already has a firm foothold in cancer thanks to its immunotherapy Keytruda (pembrolizumab), which has been on the market for several years and has proven to […]

  • ANGLE raises £20m, eyes opportunity in immunotherapy trials

    Liquid biopsy company ANGLE has raised £20m through a conditional placing on the London Stock Exchange which will be used to expand commercial opportunities. ANGLE’s Parsortix system detects and captures circulating tumour cells (CTCs) in blood for subsequent analysis. The company believes there is huge potential for its use in assessing patient response to immunotherapy […]

  • Toxic positivity and grief: The reality of living through cancer

    Cancer doesn’t end when treatment stops – it’s a lifelong journey and people need support throughout, says patient advocate Megan-Claire Chase. No one gets through cancer unscathed. People are usually left with a mixture of treatment aftereffects, toxic positivity, and lingering anger to deal with. Megan-Claire Chase, a fierce patient advocate who has been blogging […]

  • Fujifilm & Volpara Partner to Help Clinicians Determine Patient Breast Density

    What You Should Know: – FUJIFILM Medical Systems U.S.A., Inc. and Volpara Solutions announced the extension of their partnership to provide mammography facilities and clinicians with breast imaging solutions designed to improve image quality, streamline workflow and accurately assess a patient’s breast density. – Building on a successful 6-year partnership, Fujifilm’s customers using ASPIRE Cristalle […]

  • How to Treat Polycystic Ovary Syndrome (PCOS) with Diet

    Given the role that oxidant free radicals are thought to play in aging and disease, one reason fruits and vegetables may be so good for us is that they contain antioxidant compounds. As you can see at 0:20 in my video Benefits of Marjoram for Polycystic Ovary Syndrome (PCOS), different vegetables and herbs have different […]

  • The Role of Meat and Dairy Viruses in Cancer

    “Nearly 20% of cancer cases arising worldwide can be linked to infectious agents, including viruses.” Seven viruses are now conclusively tied to human cancers, and, as new viruses enter into human populations, the incidence and causes of cancer will likely change accordingly. The foundation of modern tumor virology was laid more than a century ago […]

  • UK medical journals spar over breast cancer screening study

    Screening women for breast cancer in their 40s rather than their 50s could save lives, say the authors of a new Lancet Oncology study, although that finding has been challenged by other experts. Lowering the age that women start to routinely get mammograms was associated with a relative reduction in breast cancer mortality without leading […]

  • What Explains the Egg-Cancer Connection

    The reason egg consumption is associated with elevated cancer risk may be the TMAO, considered the “smoking gun” of microbiome-disease interactions. “We are walking communities comprised not only of a Homo sapiens host, but also of trillions of symbiotic commensal microorganisms within the gut and on every other surface of our bodies.” There are more […]

  • Samsung Bioepis Launches Ontruzant (trastuzumab, biosimilar) for Early and Metastatic HER2-Overexpressing Breast Cancer in Brazil

    Shots: The company launches its first oncology treatment Ontruzant (trastuzumab), a biosimilar referencing Herceptin in Brazil. The biosimilar has received ANVISA’s approval for the treatment of metastatic HER2-overexpressing BC, early HER2-overexpressing BC, and advanced gastric cancer Ontruzant is being supplied to SUS through a PDP b/w Samsung Bioepis & Bionovis and Bio-Manguinhos. This the second […]

  • Armpit Shaving and Breast Cancer

    Shaving before applying underarm antiperspirants can increase aluminum absorption. Could this explain the greater number of tumors and the disproportionate incidence of breast cancer in the upper outer quadrant of the breast near the armpit? A famous case report called “The Mortician’s Mystery,” published in the New England Journal of Medicine back in the 1980s, […]

  • Henlius and Accord’s Zercepac (trastuzumab, biosimilar) Receive the EMA Approval for HER2-Positive Breast Cancer and Gastric Cancer

    Shots: The approval is based on comparative quality studies, clinical studies including preclinical data and resulted in bio-similarity, comparable efficacy and safety of Zercepac (HLX02) vs Herceptin Zercepac is developed under NMPA and EMA biosimilar guidelines and has been evaluated with the reference trastuzumab including comparative quality studies, preclinical studies, a P-I clinical study and […]

  • Zebra Medical Receives the US FDA’s Approval for its HealthMammo Mammography Tool

    Shots: The US FDA has granted 510 (k) clearance to HealthMammo for boosting early detection of breast cancer in mammograms The tool utilizes the AI to prioritize and identify suspicious mammograms and is automatically sent to Zebra’s platform, where it gets processed and analyzed for suspected breast lesions. The HealthMammo product then returns its result […]

  • AstraZeneca inks $6bn cancer drug deal with Daiichi Sankyo

    AstraZeneca has begun a new agreement with Daiichi Sankyo to develop and market an antibody to treat cancer, worth up to $6 billion. The deal covers DS-1062, Daiichi Sankyo’s proprietary antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2). AZ and Daiichi are already collaborating on antibody-drug candidate, Enhertu (trastuzumab deruxtecan), which is already approved in […]

  • Daiichi Sankyo Signs a Research Agreement Gustave Roussy for DS-1062 and Patritumab Deruxtecan to Treat Lung and Breast Cancer

    Shots: Gustave Roussy to receive funding and support from Daiichi Sankyo for integrative research program including clinical, translational, and preclinical studies for DS-1062 and patritumab deruxtecan in lung and breast cancer respectively The research program includes two P-II studies evaluating the efficacy, safety, and markers of response and resistance to DS-1062 & patritumab deruxtecan in […]

  • What Does Drinking Soy Milk Do to Hormone Levels?

    The vast majority of breast cancers start out hormone-dependent, where estradiol, the primary human estrogen, “plays a crucial role in their breast cancer development and progression.” That’s one of the reasons why soy food consumption appears so protective against breast cancer: Soy phytoestrogens, like genistein, act as estrogen-blockers and block the binding of estrogens, such […]

  • Are the BPA-Free Plastics Like Tritan Safe?

    Do BPA-free plastics such as Tritan, have human hormone-disrupting effects? And what about BPS and BPF? Recent human studies indicate that exposure to the plastics chemical BPA may be associated with infertility, miscarriage, premature delivery, reduced male sexual function, polycystic ovaries, altered thyroid and immune function, diabetes, heart disease, and more. Yet, “[a]s recently as […]

  • How to Treat Endometriosis with Diet

    “Endometriosis is a major cause of disability and compromised quality of life in women and teenage girls.” It “is a chronic disease which is under-diagnosed, under-reported, and under-researched…[and for patients, it] can be a nightmare of misinformation, myths, taboos, lack of diagnosis, and problematic hit-and-miss treatments overlaid by a painful, chronic, stubborn disease.” Pain is […]

  • What to Eat and Avoid for Women with BRCA Gene Mutations

    Five studies have been performed on breast cancer survival and soy foods involving more than 10,000 breast cancer patients, and together they found that those who eat more soy live longer and have a lower risk of the cancer coming back. What about women who carry breast cancer genes? Fewer than 10 percent of breast […]